Avricore Health CEO Hector Bremner discussed the company's significant growth, partnerships, and expansion into new markets during an interview with Steve Darling from Proactive.
Bremner shared how these developments position Avricore Health for future success, with a strong focus on the company's flagship product, HealthTab.
Bremner emphasized that the core of Avricore Health's operations centers around HealthTab, an innovative health monitoring solution. The company is working on expanding the reach of HealthTab by partnering with more pharmacies not only across Canada but also on a global scale.
This expansion strategy aims to bring HealthTab's benefits to a wider audience and increase the company's market presence.
Regarding financial performance, Bremner highlighted the impressive growth achieved by Avricore Health. Revenues for the first half of 2023 reached $1,177,290, representing a remarkable 437% increase compared to the same period in the previous year. This growth was attributed to the deployment of more HealthTab systems and increased tests sold.
Additionally, the company's gross profit surged by 511% to $440,152, with a gross margin of 37.39% outperforming the company's target margin of 30%. This performance underscores the solid fundamentals of the company and its ability to increase scale while simultaneously improving profitability.
Avricore Health's success story also includes its recent selection by a collaborative effort involving the renowned Barts Heart Centre and the national cardiovascular charity HEART UK.
The company was chosen to assess the feasibility of integrating cholesterol testing into community pharmacies in the UK. This initiative aims to complement opportunistic blood pressure checks, assess cardiovascular risk, and expand clinical services offered to patients.
View source version on newsdirect.com: https://newsdirect.com/news/avricore-health-ceo-feels-company-is-set-up-for-success-with-new-partnerships-and-emerging-markets-194855088
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Boston New Times journalist was involved in the writing and production of this article.